Boston Partners
CLVS

Boston Partners’s Clovis Oncology, Inc. CLVS Stock Holding History

Boston Partners’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-112,211
Closed -$1.54M – 773
2016
Q2 		$1.54M Buy
+112,211
New +$1.64M ﹤0.01% 668

Other funds holding CLVS

PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
PC
PointState Capital New York $7.82B AUM 43.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Boston Partners's CLVS Position: Q3 2016 in Review

Boston Partners sold out of Clovis Oncology, Inc. (CLVS) in Q3 2016, closing a stake of 112,211 shares — an estimated $1.54M sold.

Boston Partners first reported a position in CLVS in Q2 2016 and held it in 1 quarter. The position peaked at $1.54M in Q2 2016. 163 funds tracked by Wall St. Rank hold CLVS as of Q3 2016.

  • Boston Partners reported no remaining Clovis Oncology, Inc. position as of Q3 2016 after selling out during the quarter.
  • Boston Partners sold 112,211 Clovis Oncology, Inc. shares in Q3 2016, an estimated $1.54M.
  • Boston Partners first reported a position in Clovis Oncology, Inc. in Q2 2016 and held it in 1 quarter.
  • Boston Partners's Clovis Oncology, Inc. position peaked at $1.54M in Q2 2016.
  • 163 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q3 2016.

Based on Boston Partners's 13F filing for Q3 2016, filed 9 Nov 2016.